In the News

Dartmouth Psychiatrist Honored as Mental Health Professional of the Year for NH – Seacoast Online

Read article – Continued coverage of Mary Brunette, associate professor of psychiatry, being named the mental health professional of the year by the New Hampshire chapter of the National Alliance on Mental Illness. The award is given annually to a mental health professional who goes above and beyond for those affected by mental illness and suicide. (Picked up by Foster’s Daily Democrat.)

Fully Vaccinated People Who Got COVID-19 Describe Their Mild Symptoms, and Their Relief That They’d Gotten a Shot – Business Insider

Read article – Lisa Adams, associate dean for global health and professor of medicine, is quoted in an article on the incidence of COVID-19 infections in fully vaccinated people. “We know there are and will be some breakthrough infections in individuals who are vaccinated – at least until we get to a point where there is very little virus circulating,” Adams said. “The good news is that their illness should be very mild.”

Monthly Child Tax Credit Payments Begin This Week – WCAX

Read article – Keith Loud, chair and associate professor of pediatrics, is quoted in an article on the American Rescue Plan, new federal legislation that expands the child care tax credit. “We know the power of benefit of child health and well-being that comes from the spending we’ve heard on early childhood education, good nutrition, addressing the toxic stress of not being able to pay your bills in general,” Loud said.

FDA Warns of Possible Rare Association Between Johnson & Johnson Vaccine and Guillain-Barre Syndrome – WMUR

Read article – Michael Calderwood, associate professor of medicine, is quoted in a report linking a rare autoimmune disorder, Guillain-Barre Syndrome, with Johnson & Johnson’s COVID-19 vaccine. “Similar to what we were seeing back in April with the warnings on the Johnson & Johnson vaccine related to thrombosis and thrombocytopenia, the numbers are very small,” Calderwood said. “So, not to dismiss them, but we have to find the balance between what is a very rare side effect and what is the benefit from the vaccine itself.”

Genotyping Not Yet Appreciated as ChemoRx Tool – Clinical Oncology News

Read article – Gabriel Brooks, assistant professor of medicine and assistant professor of The Dartmouth Institute, says that pharmacogenetic testing for DPYD and UGT1A1 gene variants could be cost-effective in preventing severe chemotherapy-related toxicity based on the treatment of stage 3 colon cancer patients. Comments by Brooks are referenced in research reported at the 2021 Gastrointestinal Cancers Symposium.